EUVIMEDEUVIMED entdecken
Crossref

WATCH : A Workflow to Assess Treatment Effect Heterogeneity in Drug Development for Clinical Trial Sponsors

Konstantinos Sechidis iD, Sophie Sun, Yao Chen, Jiarui Lu, Cong Zhang, Mark Baillie, David Ohlssen, Marc Vandemeulebroecke iD, Rob Hemmings, Stephen Ruberg iD, Björn Bornkamp iD

Pharmaceutical Statistics · 2025-03 · 24 (2)

DOI: 10.1002/pst.2463 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Statistics, online erschienen am 26.12.2024. Verfasst von Konstantinos Sechidis und 10 weiteren Autor:innen. Beteiligte Einrichtung: Advanced Methodology and Data Science, Novartis Pharma AG, Basel, Switzerland. Hauptthemen laut MEDLINE: Workflow, Drug Development, Randomized Controlled Trials as Topic, Research Design. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: Novartis Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This article proposes a Workflow for Assessing Treatment effeCt Heterogeneity (WATCH) in clinical drug development targeted at clinical trial sponsors. WATCH is designed to address the challenges of investigating treatment effect heterogeneity (TEH) in randomized clinical trials, where sample size and multiplicity limit the reliability of findings. The proposed workflow includes four steps: analysis planning, initial data analysis and analysis dataset creation, TEH exploration, and multidisciplinary assessment. The workflow offers a general overview of how treatment effects vary by baseline covariates in the observed data and guides the interpretation of the observed findings based on external evidence and the best scientific understanding. The workflow is exploratory and not inferential/confirmatory in nature but should be preplanned before database lock and analysis start. It is focused on providing a general overview rather than a single specific finding or subgroup with a differential effect.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

WorkflowDrug DevelopmentRandomized Controlled Trials as TopicResearch DesignHumansSample SizeTreatment OutcomeData Interpretation, StatisticalTreatment Effect Heterogeneity

Stichwörter der Autor:innen

heterogeneous treatment effectsmachine learningsubgroup analysissubgroup identification

Autor:innen und Institutionen

  • Advanced Methodology and Data Science, Novartis Pharma AG, Basel, Switzerland.
  • Advanced Methodology and Data Science, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
  • Department of Biostatistics, Vertex Pharmaceuticals, Boston, Massachusetts, USA.
  • China Novartis Institutes for Bio-Medical Research Co, Shanghai, China.
  • Development Analytics and Statistical Innovation, UCB Farchim SA, Bulle, Switzerland.
  • Consilium Hemmings (UK) Ltd, Woking, UK.

ORCID-Profile: Konstantinos Sechidis, Marc Vandemeulebroecke, Stephen Ruberg, Björn Bornkamp

Förderung

  • Novartis Pharma

Zitieren

APA

Sechidis, K., Sun, S., Chen, Y., Lu, J., Zhang, C., Baillie, M., Ohlssen, D., Vandemeulebroecke, M., Hemmings, R., Ruberg, S., & Bornkamp, B. (2025). WATCH : A Workflow to Assess Treatment Effect Heterogeneity in Drug Development for Clinical Trial Sponsors. Pharmaceutical Statistics, 24(2). https://doi.org/10.1002/pst.2463

Vancouver

Sechidis K, Sun S, Chen Y, Lu J, Zhang C, Baillie M, et al. WATCH : A Workflow to Assess Treatment Effect Heterogeneity in Drug Development for Clinical Trial Sponsors. Pharmaceutical Statistics. 2025;24(2). doi:10.1002/pst.2463

BibTeX
@article{Sechidis2025,
  author = {Sechidis, Konstantinos and Sun, Sophie and Chen, Yao and Lu, Jiarui and Zhang, Cong and Baillie, Mark and Ohlssen, David and Vandemeulebroecke, Marc and Hemmings, Rob and Ruberg, Stephen and Bornkamp, Björn},
  title = {WATCH : A Workflow to Assess Treatment Effect Heterogeneity in Drug Development for Clinical Trial Sponsors},
  journal = {Pharmaceutical Statistics},
  year = {2025},
  volume = {24},
  number = {2},
  doi = {10.1002/pst.2463}
}
Kostenlos starten →